🐦 推特Adam Feuerstein (STAT)Codex · 实盘不做把握 6/10
北京时间·🕒 发布 07-28 20:03:27时区推断·⟳ 抓取 02:08:04回填·⚡ 决策 07-30 02:11:42·89.8 天前
FDA简报文件重申Replimune的RP1疗效证据不足并质疑IGNYTE终点可靠性
FDA在7月30日咨询委员会前发布的简报文件重申RP1单臂试验不足以证明有效性，并指出RECIST v1.1应用问题可能人为抬高ORR和DOR。
📄 原文Adam Feuerstein (STAT)@adamfeuerstein↗ 原文
Unsure why anyone would have expected the FDA review of $REPL in the briefing documents to look different from the two…
不做 Replimune Group（REPL.US）
事件方向明确偏空，但REPL已在FDA文件公开后大幅下跌且未取得Futu可借券库存确认，不能开SHORT；负面仅保留为风险信号，禁止因超跌反手做多。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- FDA在7月30日CTGTAC会议页面发布RP1相关FDA与Sponsor简报文件、议程和投票问题，构成一手监管材料。
- Investing.com报道FDA文件列出关键疗效审查问题，称REPL盘前下跌约20%。市场反应:盘前已明显下跌。
- Adam Feuerstein摘引FDA文件中关于RECIST、ORR/DOR、RP1贡献和加速批准要求的负面段落，说明文件与此前两次CRL方向一致。
- Dow Jones称FDA认为重新提交材料仍未提供充分且良好对照研究，股票盘中一度跌约32%。市场反应:报道时REPL约跌32%。
- STAT报道FDA工作人员重申Replimune没有足够数据支持RP1获批，并突出单臂试验和系统性获益证据问题。
- 2026-07-28市场反应Futu行情非一手REPL在FDA文件公开后的7月28日收跌38.01%，7月29日研判时仅小幅反弹。市场反应:7月28日-38.01%，7月29日盘中约+1.50%。
关键理由
- FDA在7月30日咨询委员会前发布的简报文件重申RP1单臂试验不足以证明有效性，并指出RECIST v1.1应用问题可能人为抬高ORR和DOR。
- RP1已历经两次CRL，本次文件没有显示关键缺陷被实质解决，短期监管通过概率继续受压。
- Replimune（REPL.US）现价约5.43美元，7月28日已因文件大跌38%，负面已部分兑现，剩余交易更偏风控而非追空。
主要风险
- 7月30日ODAC投票或FDA最终决定若意外支持RP1，低价小盘生物科技股可能快速反弹。
- 当前未取得Futu可借券库存确认，且事件后已大幅下跌，不能裸开空也不应以“跌多了”反手做多。
反向证据
- 做空前查反向 · 来源 kb_search · 影响 none
内部KB未命中RP1本次ODAC前足以抵消FDA简报负面的正面研报或确认性利好。
检索:Replimune RP1 advisory committee positive support melanoma July 2026 FDA counter evidence - 做空前查反向 · 来源 kb_search · 影响 none
内部KB未命中同一事件的高质量付费平台反向解释，结果主要为无关命中。
检索:Replimune RP1 FDA briefing documents RECIST ORR DOR July 2026 ODAC - 做空前查反向 · 来源 web · 日期 2026-07-28 · 影响 supports
公开报道与FDA页面均指向审评团队继续质疑疗效证据，支持看空方向但股票已明显重定价。
检索:Replimune FDA briefing document RP1 IGNYTE artifactually inflated ORR DOR 原文 ↗
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 835 字
Unsure why anyone would have expected the FDA review of $REPL in the briefing documents to look different from the two CRLs already issued.
It does not.
"FDA identified several issues with the Applicant’s application of RECIST v1.1 criteria that
were used for response assessment. The FDA review team concludes that these artifactually inflated the
primary endpoints of the IGNYTE trial, ORR and DOR. The contribution of RP1 to the combination effect
cannot be determined, and it is unclear if RP1 contributes to any observed effect. Overall survival data
from the single-arm trial are not interpretable for establishing a treatment effect. Without definitive
evidence of systemic effect, the response rate cannot be considered reasonably likely to predict clinical
benefit per the statutory requirements for accelerated approval."
It does not.
"FDA identified several issues with the Applicant’s application of RECIST v1.1 criteria that
were used for response assessment. The FDA review team concludes that these artifactually inflated the
primary endpoints of the IGNYTE trial, ORR and DOR. The contribution of RP1 to the combination effect
cannot be determined, and it is unclear if RP1 contributes to any observed effect. Overall survival data
from the single-arm trial are not interpretable for establishing a treatment effect. Without definitive
evidence of systemic effect, the response rate cannot be considered reasonably likely to predict clinical
benefit per the statutory requirements for accelerated approval."
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。